Human papillomavirus 6/11 vaccine recombinant bivalent - Xiamen Innovax

Drug Profile

Human papillomavirus 6/11 vaccine recombinant bivalent - Xiamen Innovax

Alternative Names: Gecolin; Human papillomavirus (types 6 and 11) L1 virus-like particle vaccine - Xiamen Innovax; Human papillomavirus 6/11 bivalent vaccine - Xiamen; Human papillomavirus 6/11 vaccine - Xiamen; Recombinant human papillomavirus type 6/11 bivalent vaccine - Xiamen Innovax

Latest Information Update: 24 Mar 2016

Price : $50

At a glance

  • Originator Xiamen Innovax Biotech
  • Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Condylomata acuminata

Most Recent Events

  • 12 Mar 2016 Xiamen Innovax Biotech, Beijing Wantai Bio-pharm and Xiamen University plan a phase II trial for Condylomata acuminata (Prevention, In volunteers) in China (IM) (NCT02710851)
  • 01 Mar 2015 Preclinical trials in Condylomata acuminata in China (IM)
  • 01 Mar 2015 Xiamen Innovax and Beijing Wantai Bio-pharm plan a phase I trial for Condylomata acuminata (Prevention) in China (NCT02405520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top